This in-depth feature explores SpotitEarly’s at-home, breath-based cancer screening test, which combines trained detection dogs with the proprietary LUCID AI platform to identify cancer-related odor signatures at the earliest stages. The article highlights the company’s focus on accessibility, non-invasive screening, and integration alongside existing diagnostic tools.

SpotitEarly was recognized on the 2025 New Jersey Business Power List for its innovative approach to early cancer detection using trained canines and artificial intelligence. Following a $20.3 million raise and U.S. market entry, the article also notes SpotitEarly’s research collaboration with Hackensack as a key step toward advancing proactive cancer screening in the United States.

Islander News reports on how artificial intelligence is reshaping breast cancer screening by helping clinicians move beyond one-size-fits-all guidelines toward more individualized risk assessment. The article highlights emerging AI tools that analyze large datasets of mammograms and patient outcomes, while also featuring SpotitEarly’s approach to using AI to analyze subtle behavioral signals from trained disease-detection dogs. 

This Diversity in Action feature profiles SpotitEarly’s multidisciplinary approach to early cancer detection, combining trained detection dogs, molecular biology, and artificial intelligence. The piece underscores how cross-disciplinary expertise enables new, non-invasive screening models with the potential to improve survival outcomes.

In an interview with Cheddar, SpotitEarly CEO Dr. Shlomi Madar discusses the company’s unique approach to early cancer detection. The interview explores the science behind scent-based diagnostics, the clinical progress to date, and SpotitEarly’s vision for making early detection more accessible.

ROI-NJ featured our collaboration with Hackensack Meridian Health, highlighting the launch of the Pink Study, a large-scale clinical program using trained dogs and AI to support early cancer detection.

Fierce Healthcare covered our U.S. clinical partnership with Hackensack Meridian Health, detailing how SpotitEarly’s breath-based approach combines canine scent detection with AI analysis to identify early cancer signatures.

Discover Pharma covers our joint effort with Hackensack Meridian to validate trained-dog diagnostics alongside our AI system for non-invasive cancer screening.

HealthLeaders features a quick video segment where our CEO and team discuss how our dogs are trained to detect volatile organic compounds linked to cancer.

MedCity News reports on the launch of the Pink Study, spotlighting how we’re integrating canine scent analysis and AI in a rigorous, double-blind clinical setting.

NJBIZ features SpotitEarly’s New Jersey roots and our collaboration with HMH to advance non-invasive, canine-assisted cancer screening.

This Week Health covers how our Pink Study applies AI interpretation to canine scent responses for novel cancer screening in the U.S.

Towards Healthcare discusses our vision for pairing AI with canine olfaction to make breath-based cancer detection accessible and effective.

TechCrunch profiles SpotitEarly at Disrupt 2025, explaining how our approach uses trained dogs, breath samples, and AI to detect multiple cancers.

Observer Voice republishes TechCrunch’s coverage of our work using trained dogs and AI to sniff out cancer from breath samples.

Yahoo Tech syndicated TechCrunch’s feature on SpotitEarly’s technology blending canine scent detection and AI for non-invasive cancer screening.

Axios explores how AI is driving personalized screening recommendations - and mentions SpotitEarly’s breath test using dogs + AI as part of that shift.

A feature on our partnership with Hackensack Meridian Health exploring how trained dogs + AI might detect cancer from breath samples through volatile organic compounds.

Healthcare Finance News announces how HMH and SpotitEarly are joining forces to explore combining artificial intelligence and canine olfaction in cancer screening.

MobiHealthNews covers our joint effort to test canine scent detection alongside AI to bring noninvasive cancer screening closer to clinical use.

BINJE frames our research as part of a shift toward noninvasive diagnostic methods that merge biology and data science to improve early cancer detection.

We’re honored to be part of the 2025 SB200 cohort at TechCrunch Disrupt (Oct 27–29). Selection includes demo opportunities, investor exposure, and a chance to compete for the $100,000 equity-free prize and the Disrupt Cup.

Our COO, Udi Bobrovsky, penned a feature on our “bio-AI hybrid” platform, why canine olfaction plus deep learning matters for early detection, how LUCID enables scale (1M+ samples per facility), and performance highlights from trials across four cancers.

Bloomberg’s newsletter spotlighted SpotitEarly’s model of combining trained canines with AI for earlier detection, noting recent fundraising and the promise of breath-based screening.

Citeline highlighted our U.S. expansion and trial activity for a dog-and-AI powered early-detection test; the piece notes our new U.S. HQ and ongoing clinical work.

An interview on our bio-AI approach: capturing dogs’ ultra-sensitive scent responses to VOCs and interpreting them with our LUCID platform. It discusses at-home breath collection, clinical validation underway, and the goal of accessible, high-accuracy multi-cancer screening.

Business Insider’s overview of at-home colon-cancer screening calls out breath testing as a promising, easy alternative and mentions SpotitEarly’s breath test targeting U.S. availability pending FDA review, with company-sponsored data on early-stage detection.

Our CEO, Shlomi Madar, Ph.D., was named to NJBIZ’s “2025 People to Watch in Health Care,” highlighting innovators improving access to early detection. The feature notes SpotitEarly’s mission to make screening more widely available.

A founder-focused, one-day summit (July 15, 2025) covering practical topics like cap-table management, investor expectations, fundraising tactics and the 2025 VC landscape. Our team joined to learn, meet fellow builders and connect with people tackling meaningful problems.

in an in-depth piece titled “SpotitEarly’s New Early Cancer Detection Breath Test Is Powered by AI and Dogs.” The article highlights how our innovative screening method uses a combination of trained detection dogs and AI to analyze breath samples for early signs of cancer, tackling the persistent gap between medical innovation and accessibility.

SpotitEarly featured in the latest white paper, a collaboration between C4IR (Serbia), Office for IT and eGovernment, C4IR Israel, and Israel Innovation Authority.

Our latest review article: "Innovative Approaches to Early Detection of Cancer – Transforming Screening for Breast, Lung, and Hard-to-Screen Cancers", published in Cancers. In this paper, we explore the scientific and clinical progress in non-invasive cancer screening technologies.

“The nose knows: How dogs and AI are reinventing cancer detection” offers an in-depth look at how behavioral analysis, biological sensitivity, and system design come together in our approach.

Our CEO, Shlomi Madar, was interviewed by NJBIZ, where he shared insights into our tech-powered, dog-assisted approach to early cancer detection, and what’s next for SpotItEarly. The interview dives into our clinical results, the role of AI in standardizing detection, and how we’re working to make breath-based screening accessible and scalable.

The article describes how users can simply breathe into a mask, ship it back, and receive results based on a unique bio-AI system that includes trained dogs sniffing for early cancer markers. The Post praises the blend of “puppy power” and AI as a promising non-invasive solution for early diagnosis.

The Jerusalem Post featured SpotitEarly’s breath-based cancer screening in a detailed article under its Health & Wellness section. The article highlights the company’s clinical results, simplicity of the test, and its potential to reshape early detection on a global scale

In this feature by Newsweek, SpotitEarly  is highlighted as part of a new wave of innovation focused on early cancer detection. The article explores the promise of biotech breakthroughs, including our unique approach, while emphasizing the need for more equitable access to life-saving screening technologies.

Dogs’ ability to detect cancer is no longer just anecdotal, this piece explores how SpotitEarly's AI-powered breath test could revolutionize early cancer detection.

SpotitEarly's innovative approach combining canine scent detection with AI is making waves in the medical community, offering a non-invasive method for early cancer screening.

Shlomi Madar discusses the company's innovative approach to early cancer detection. He shares insights into how combining canine scent detection with artificial intelligence can transform non-invasive cancer screening.

SpotitEarly, in partnership with Penn Medicine, was awarded an investment from the BIRD Foundation. This collaboration aims to develop, test, and validate an early cancer detection technology that combines AI with dogs' highly sensitive sense of smell.

GlobalPost covers how SpotitEarly's unique combination of trained canines and artificial intelligence is setting new standards in early cancer detection.

An in-depth look at how SpotitEarly integrates canine olfaction with AI to create a groundbreaking, non-invasive cancer screening method.